HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Cites Adulteration In Warning Letter To Juice Beauty Manufacturer

This article was originally published in The Rose Sheet

Executive Summary

FDA’s latest warning letter to a cosmetics firm departs from the agency’s crackdown on drug-like structure/function claims, targeting contract manufacturer Gemdo Cosmetics for facility conditions and evidence of microbial contamination that cause its products to be adulterated under the Federal Food, Drug and Cosmetic Act. In the April 16 letter, FDA cites eye products produced at the firm’s plant, including Juice Beauty offerings subject to a July 2014 recall.

You may also be interested in...



What Comes First In Consumer Sector: FDA Excessive Claims Finding Or Facility Inspection?

Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections.

What Comes First In Consumer Sector: FDA Excessive Claims Finding Or Facility Inspection?

Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections.

What Comes First? FDA Excessive Claims Finding Or Facility Inspection?

Recent warning letters to Reviva Labs and Ageless Derma manufacturer Crescent Health Center cite claims violations brought to FDA's attention through inspections of the companies' facilities. It's possible, however, that conspicuous website claims that overstep cosmetic boundaries are prompting inspections.

Related Content

UsernamePublicRestriction

Register

RS019474

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel